General

Title
Substance use disorders: percentage of patients aged 18 years and older with a diagnosis of current alcohol dependence who were counseled regarding psychosocial AND pharmacologic treatment options for alcohol dependence within the 12 month reporting period.

Source(s)


Measure Domain

Primary Measure Domain

Process
The validity of measures depends on how they are built. By examining the key building blocks of a measure, you can assess its validity for your purpose. For more information, visit the Measure Validity page.

Secondary Measure Domain

Does not apply to this measure

Brief Abstract

Description
This measure is used to assess the percentage of patients aged 18 years and older with a diagnosis of current alcohol dependence who were counseled regarding psychosocial AND pharmacologic treatment options for alcohol dependence within the 12 month reporting period.

Rationale
Research has shown that among patients diagnosed with alcohol dependence, only 4.64% were referred for psychosocial treatment in the form of substance abuse counseling, inpatient rehabilitation programs, outpatient rehabilitation programs, or mutual help groups. While pharmacologic therapy has established efficacy, often in combination with psychosocial therapy, in promoting abstinence and preventing relapse in alcohol-dependent patients, physician rates of prescribing pharmacologic therapy for alcohol dependence are also considerably low. A recent study found that these low rates prevail even among addiction medicine physicians who prescribed naltrexone to only 13% of their alcohol dependent patients.
Pharmacotherapy and psychosocial treatment should be routinely considered for all patients with alcohol dependence, and patients should be informed of this option.

The following clinical recommendation statements are quoted verbatim from the referenced clinical guidelines (from the American Psychiatric Association [APA]) and represent the evidence base for the measure:

Psychosocial treatments found effective for some patients with an alcohol use disorder include motivational enhancement therapy (MET), cognitive-behavioral therapy (CBT), behavioral therapies, 12-step facilitation (TSF), marital and family therapies, group therapies, and psychodynamic therapy/interpersonal therapy (IPT). (APA, 2006)

Specific pharmacotherapies for alcohol-dependent patients have well-established efficacy and moderate effectiveness:

- Naltrexone may attenuate some of the reinforcing effects of alcohol, although data on its long-term efficacy are limited. The use of long-acting, injectable naltrexone may promote adherence, but published research is limited and FDA approval is pending. [Note: Extended-release naltrexone for injection has since received FDA approval]
- Acamprosate, a gamma-aminobutyric acid (GABA) analog that may decrease alcohol craving in abstinent individuals, may also be an effective adjunctive medication in motivated patients who are concomitantly receiving psychosocial treatment.
- Disulfiram is an effective adjunct to a comprehensive treatment program for reliable, motivated patients whose drinking may be triggered by events that suddenly increase alcohol craving. (APA, 2006)

Empirically validated psychosocial treatment interventions should be initiated for all patients with substance use illnesses. Pharmacotherapy should be offered and available to all adult patients diagnosed with alcohol dependence and without medical contraindications. Pharmacotherapy, if prescribed, should be provided in addition to and directly linked with psychosocial treatment/support. (National Quality Forum [NQF], 2007)

Primary Clinical Component

Alcohol dependence; psychosocial counseling; pharmacologic treatment

Denominator Description

All patients aged 18 years and older with a diagnosis of current alcohol dependence

Numerator Description

Patients who were counseled regarding psychosocial AND pharmacologic treatment options for alcohol dependence within the 12 month reporting period

Evidence Supporting the Measure

Evidence Supporting the Criterion of Quality

A clinical practice guideline or other peer-reviewed synthesis of the clinical evidence

One or more research studies published in a National Library of Medicine (NLM) indexed, peer-reviewed journal

Evidence Supporting Need for the Measure

Need for the Measure

Overall poor quality for the performance measured

Use of this measure to improve performance

Evidence Supporting Need for the Measure
State of Use of the Measure

State of Use

Current routine use

Current Use

Internal quality improvement

Application of Measure in its Current Use

Care Setting

Ambulatory Care

Community Health Care

Physician Group Practices/Clinics

Professionals Responsible for Health Care

Physicians

Psychologists/Non-physician Behavioral Health Clinicians

Social Workers

Lowest Level of Health Care Delivery Addressed

Individual Clinicians

Target Population Age

Age greater than or equal to 18

Target Population Gender

Either male or female

Stratification by Vulnerable Populations
Characteristics of the Primary Clinical Component

Incidence/Prevalence
See the "Rationale" field.

Association with Vulnerable Populations
Unspecified

Burden of Illness
Unspecified

Utilization
Unspecified

Costs
Unspecified

Institute of Medicine (IOM) Healthcare Quality Report Categories

IOM Care Need
Getting Better
Living with Illness

IOM Domain
Effectiveness
Patient-centeredness

Data Collection for the Measure

Case Finding
Users of care only

Description of Case Finding
Patients aged 18 years and older with a diagnosis of current alcohol dependence

**Denominator Sampling Frame**

Patients associated with provider

**Denominator Inclusions/Exclusions**

**Inclusions**
All patients aged 18 years and older with a diagnosis of current alcohol dependence

**Exclusions**
None

**Relationship of Denominator to Numerator**

All cases in the denominator are equally eligible to appear in the numerator

**Denominator (Index) Event**

**Clinical Condition**

**Encounter**

**Denominator Time Window**

Time window is a single point in time

**Numerator Inclusions/Exclusions**

**Inclusions**
Patients who were counseled regarding psychosocial AND pharmacologic treatment options for alcohol dependence within the 12 month reporting period

**Exclusions**
None

**Measure Results Under Control of Health Care Professionals, Organizations and/or Policymakers**

The measure results are somewhat or substantially under the control of the health care professionals, organizations and/or policymakers to whom the measure applies.

**Numerator Time Window**

Encounter or point in time

**Data Source**

Administrative data
Medical record

Level of Determination of Quality
Individual Case

Pre-existing Instrument Used
Unspecified

Computation of the Measure

Scoring
Rate

Interpretation of Score
Better quality is associated with a higher score

Allowance for Patient Factors
Unspecified

Standard of Comparison
Internal time comparison

Evaluation of Measure Properties

Extent of Measure Testing
Unspecified

Identifying Information

Original Title
Measure #1: counseling regarding psychosocial and pharmacologic treatment options for alcohol dependence.

Measure Collection Name
The Physician Consortium for Performance Improvement® Measurement Sets
Measure Set Name
Substance Use Disorders Physician Performance Measurement Set

Submitter
American Medical Association on behalf of the American Psychiatric Association, Physician Consortium for Performance Improvement®, and National Committee for Quality Assurance - Medical Specialty Society

Developer
American Psychiatric Association - Medical Specialty Society
National Committee for Quality Assurance - Health Care Accreditation Organization
Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration

Funding Source(s)
Unspecified

Composition of the Group that Developed the Measure
Daniel Kivlahan, PhD (Co-Chair); Mark L. Willenbring, MD (Co-Chair); James G. Adams, MD; Joann Albright, PhD; Charles E. Argoff, MD; Ray M. Baker, MD; Richard L. Brown, MD, MPH; Audrey Bumam, PhD; Mirean Coleman, MSW, LICSW, CT; Edward C. Covington, MD; Thomas J. Craig, MD, MPH; Ann Doucette, PhD; Larry M. Gentilello, MD; Eric Goplerud, PhD, MA; Constance Horgan, ScD; Herbert D. Kleber, MD; Petros Levounis, MD; Bertha K. Madras, PhD; Frank McCorry, PhD; Ann H. Messer, MD; Michael M. Miller, MD, FASAM, FAPA; Doug Nemecek, MD, MBA; Harold Alan Pincus, MD; Rhonda Robinson-Beale, MD; Richard N. Rosenthal, MD; Darlene Warrick McLaughlin, MD; Scott C. Williams, PsyD
Beatrice Eld, American Psychiatric Association; Robert Plovnick, MD, MS, American Psychiatric Association
Joseph Gave, MPH, American Medical Association; Karen Kmetk, PhD, American Medical Association; Shannon Sims, MD, PhD, American Medical Association; Samantha Tierney, MPH, American Medical Association; Richard Yoast, PhD, American Medical Association
Lisa Nern, MSW, National Committee for Quality Assurance; Philip Renner, MBA, National Committee for Quality Assurance
Sylvia Puhl, MBA, RHIA, Centers for Medicare & Medicaid Service
Rebecca Kresowik, PCPI Consultant; Timothy Kresowik, MD PCPI Consultant

Financial Disclosures/Other Potential Conflicts of Interest
Conflicts, if any, are disclosed in accordance with the Physician Consortium for Performance Improvement® conflict of interest policy.

Included in
Ambulatory Care Quality Alliance

Adaptation
Measure was not adapted from another source.
Measure Availability

The individual measure, "Measure #1: Counseling Regarding Psychosocial and Pharmacologic Treatment Options for Alcohol Dependence," is published in the "Substance Use Disorders Physician Performance Measurement Set." This document and technical specifications are available in Portable Document Format (PDF) from the American Medical Association (AMA)-convened Physician Consortium for Performance Improvement® Web site: www.physicianconsortium.org.

For further information, please contact AMA staff by e-mail at cqi@ama-assn.org.

NQMC Status

This NQMC summary was completed by ECRI Institute on June 25, 2008. The information was verified by the measure developer on August 13, 2008. The information was reaffirmed by the measure developer on November 17, 2010.

Copyright Statement

© 2008 American Medical Association and National Committee for Quality Assurance. All Rights Reserved.

CPT® Copyright 2007 American Medical Association

Disclaimer

NQMC Disclaimer

The National Quality Measures Clearinghouse® (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.
Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria.

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.